item management s discussion and analysis of financial condition and results of operations the company has generated limited revenues from product sales and is dependent upon external financing  interest income  and research and development contracts to pursue its intended business activities 
the company has not been profitable since inception and has incurred a cumulative net loss of  through december  losses have resulted principally from costs incurred in research activities aimed at identifying and developing the company s product candidates  clinical research studies  merger and acquisition costs  the write off of purchased research and development  and general and administrative expenses 
the company expects to incur additional operating losses over the next several years as the company s research and development and clinical trials programs continue 
the company s ability to achieve profitability is dependent on its ability to develop and obtain regulatory approvals for its products  to enter into agreements for product development and commercialization with strategic corporate partners and to develop the capacity to manufacture and sell its products  and to secure additional financing 
see management s discussion and analysis of financial condition and results of operations liquidity and capital resources 
results of operations years ended december  and total revenues increased by  from  in to  in this increase resulted from a fee the company received as a result of sublicensing certain technologies which were not being actively developed by the company 
revenues in related to sales of fine chemicals 
the company phased out the selling of specialty chemicals and no such revenues were received in total operating expenses decreased by  or  from  in to  in primarily due to decreases in research and development expenses  patent expenses and general and administrative expenses 
research and development expenses decreased by  or  primarily due to clinical trials of the company s lead product lotemax tm being substantially completed in  the company submitted a new drug application nda for this product with the federal drug administration fda in march late in  the company began clinical trial testing on one of its lotemax line extension products and such trials are expected to continue into patent expenses decreased by  or  in this decrease reflects a return to more normalized levels of patent expenses as was impacted by costs of defending patent challenges related to technologies licensed by the company 
in addition patent expenses in were impacted by costs associated with improving the company s patent coverage for its lead product lotemax tm and its dexinabinol and tamoxifen methiodide compounds 
general and administrative expenses decreased by  or  in primarily reflecting the impact of the cost savings which resulted from the company s decisions in late and early to eliminate staff and relocate its corporate headquarters from new york to alachua  florida 
in the company recognized costs of approximately  related to this restructuring primarily related to severance and relocation expenses 
net interest income in of  represented an increase of compared to  and was comprised of interest income of  offset by interest expense of  interest income in increased by  or  compared to and resulted from the company s higher level of investible funds in interest expense in increased by  or compared to and resulted from interest expense on the convertible debentures issued by the company in february and converted into common stock by july the net loss for of  reflected a decrease of  or  from the net loss of  for the decrease in operating expenses described above accounted for substantially all of this decrease 
years ended december  and total revenues decreased by  or  from  in to  in the company is phasing out the sale of specialty chemicals and has already phased out specialized research contracts conducted for outside parties in favor of developing patented  proprietary pharmaceuticals 
total operating expenses increased by  or  from  in to  in primarily due to increases in research and development and phase iii clinical trials for the company s lead compound  lotemaxtm 
research and development expenses increased by  or  from  in to  in  as the number of research personnel  research expenses  and clinical trial programs expanded 
patent expenses increased by  or  from  in to  in this is primarily due to the advancement of product development and reimbursements to the university of florida for patent expenses incurred under the terms of the company s license agreement 
general and administrative expenses increased by  or  from  in to  in these increases were caused primarily by the expansion of staff in the first half of  and the subsequent restructuring costs  including severance expenses of  incurred in the second half of in addition  during the company had been working to raise funds through various financing  which were unsuccessful 
the related costs of these financing  such as travel  printing  legal and accounting fees  are a component of the increase in general and administrative expenses 
net interest income of  for was comprised of interest income of  offset by interest expense of  net interest income of  for was comprised of interest income of  and interest expense of  the decrease in interest income from to of  or  results from smaller balances of funds and the general decline in interest rates in the increase in interest expense of  or  between and primarily reflects costs related to financing activity in the form of a loan and a line or credit obtained by the company s israeli subsidiary  pharmos ltd 
the net loss for of  reflected an increase of  or  from the net loss of  for the increase of research and development  and general and administrative expenses detailed above account for the majority of the increase in net loss 
liquidity and capital resources the company currently has no sources of recurring revenues and has incurred operating losses since its inception and has financed its operations with public and private offerings of securities  a marketing agreement with bausch lomb  research contracts  license fees  royalties and sales  and interest income 
the company had working capital of million  including cash and cash equivalents of million as of december  management believes that existing cash and cash equivalents combined with additional cash inflows from investment income  grants and advances pursuant to the marketing agreement described below  will be sufficient to support operations through the first quarter of management believes that additional funding will be required to fund operations until  if ever  profitable operations can be achieved 
therefore  the company is continuing to actively pursue various funding options  including additional equity offerings  commercial and other borrowings  strategic corporate alliances and business combination transactions  the establishment of product related research and development limited partnerships  or a combination of these methods for obtaining the additional financing that would be required to continue the research and development necessary to complete the development of its products and bring them to commercial markets 
during  the company raised additional equity of  through the issuance of  shares of common stock 
a portion of these funds   net of short term deposits securing such borrowings  were used to pay off short term bank debt and the remaining funds were available to fund ongoing operations of the company 
in addition  during  the company signed a definitive marketing agreement the marketing agreement with bausch lomb to market lotemax tm  the company s lead product  on an exclusive basis in the united states 
under the marketing agreement  bausch lomb will purchase the active drug substance from the company and provide the company with million in cash advances through march an additional million in advances may be made subject to reaching certain development milestones in the lotemax tm line extension products 
bausch lomb will also collaborate in the development of such additional products by making available amounts up to of the phase iii clinical trial costs 
as of the date hereof  the company has received  in advances against future sales to bausch lomb of the active drug substance needed to manufacture the drug 
bausch lomb will be entitled to credits against such future purchases of the drug substance based on the advances and future advances until the advances have been recouped 
the company may be obligated to repay such advances if it is unable to supply bausch lomb with certain specified quantities of the active drug substance 

